Trials / Completed
CompletedNCT00444522
Staccato Alprazolam Single Dose PK
Safety, Tolerability, and Pharmacokinetics of a Single Dose of StaccatoTM Alprazolam for Inhalation in Normal, Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Alexza Pharmaceuticals, Inc. · Unknown
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
We are developing Staccato Alprazolam for the acute treatment of panic attacks associated with panic disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alprazolam thermal aerosol |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2007-03-08
- Last updated
- 2017-03-14
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00444522. Inclusion in this directory is not an endorsement.